After netting its Series D round of funding in June, Resilience is not sitting around and resting on its laurels.
The Bob Nelsen-backed contract manufacturer on Monday announced a new strategic collaboration with the Mayo Clinic. The relationship is centered around manufacturing biotherapeutics for rare and complex conditions, with the focus on biologics including those based in cells, blood, enzymes, tissues, genes or genetically engineered cells.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,000+ biopharma pros reading Endpoints daily — and it's free.
"gossip" - Google News
August 16, 2022 at 08:12PM
https://ift.tt/Nk7QmOr
Gossip in Babylon: Digital health company paints M&A rumors as flat-out wrong - Endpoints News
"gossip" - Google News
https://ift.tt/Wmcs4Kh
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
No comments:
Post a Comment